Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 4/20 | 0.41 |
| ▸ | IGF1R | P08069 | 3/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24828685 | 0.77 | PDE2A (0.33) | PDE2A | |
| SCHEMBL24828663 | 0.75 | TDP1 (0.39) | PDE2AKCNH2 | |
| SCHEMBL24828465 | 0.71 | GRIN2B (0.34) | PDE2A | |
| SCHEMBL31010253 | 0.69 | KMT2A (0.52) | PDE2AIGF1RDRD2DRD4DRD3 | |
| SCHEMBL3931966 | 0.69 | NOTUM (0.43) | IGF1RDRD2DRD4DRD3CHRNB2 | |
| SCHEMBL24007232 | 0.69 | MAPK14 (0.36) | IGF1RDRD2DRD4DRD3CHRNB2 | |
| SCHEMBL9629513 | 0.69 | NOTUM (0.43) | IGF1RDRD2DRD4DRD3CHRNB2 | |
| SCHEMBL11613001 | 0.67 | IGF1R (0.40) | IGF1RCHRNB2CHRNA4 | |
| SCHEMBL9629655 | 0.66 | NOTUM (0.43) | IGF1RCHRNB2CHRNA4 | |
| SCHEMBL20305411 | 0.65 | IGF1R (0.36) | IGF1RDRD2DRD4DRD3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, CYP3A43 | PDE2A 4184/4885IGF1R 3318/4885DRD2 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.